With the increase in use of CBD amongst professionals, the questions is often asked- “Will CBD make me fail a drug test?”. The answer to this question is not quite straight forward, but we do have some answers for you.
CBD itself will not show up on a drug test for marijuana. However, many CBD products are “Full Spectrum“, meaning they contain .3% of THC or less by law. This amount of THC is not enough to get you high, but can build up in your system and be stored in your fat if used over a long period of time (1). A study done in November of 2020 drug tested people using a full spectrum CBD product over the course of four weeks. At the end of the study, 7 participants or about (50%) of the people tested positive for THC (2). So why did only half show up positive? Well, everybody’s metabolism is different- this is why some people can eat a bowl of ice cream every night before bed and be fine, but if I even look at a cookie I might as well buy a treadmill. This is the same when it comes to processing and storing THC in the body.
This means that if you have a job that requires random drug tests, choosing a full spectrum CBD product wouldn’t be a good choice. Fortunately, we also offer broad spectrum CBD products. Broad spectrum products have all the THC remediated out. This means that you can get all the benefits of CBD but do not have to not worry about failing a drug test. Broad spectrum simply means that the product has all of the cannabinoids that a full spectrum product would, just not the THC. When looking for a broad spectrum product, make sure to also look for the terms “non-detectable THC”, or “THC remediated”.
Gunasekaran N, Long LE, Dawson BL, et al. Reintoxication: the release of fat-stored delta(9)-tetrahydrocannabinol (THC) into blood is enhanced by food deprivation or ACTH exposure. Br J Pharmacol. 2009;158(5):1330-1337. doi:10.1111/j.1476-5381.2009.00399.x https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2782342/
Dahlgren MK, Sagar KA, Lambros AM, Smith RT, Gruber SA. Urinary Tetrahydrocannabinol After 4 Weeks of a Full-Spectrum, High-Cannabidiol Treatment in an Open-label Clinical Trial. JAMA Psychiatry. 2021;78(3):335–337. doi:10.1001/jamapsychiatry.2020.3567